A



	Age groups	<6 m	6-11 m	1 y	2 y	3 y	4 y	5-6 y	7-11 y	12-17 y	≥18 y	All age groups
Male	N	16	36	70	32	32	17	24	31	20	7	285
	Seropositive cases (%)	8 (50)	1 (3)	11 (16)	13 (41)	16 (50)	13 (76)	17 (71)	25 (81)	19 (95)	4 (57)	127 (45)
	GMT	8.6	5.4	9.2	23.5	25.9	55.4	48.3	40.0	38.6	9.5	26.5
Female	N	14	19	40	33	26	14	19	41	41	47	294
	Seropositive cases (%)	4 (29)	2 (11)	3 (8)	13 (39)	11 (42)	7 (50)	16 (84)	37 (90)	36 (88)	38 (81)	167 (57)
	GMT	6.7	7.1	6.8	18.8	19.2	19.5	45.4	56.1	40.0	22.3	24.2

B



	Age groups	<6 m	6-11 m	1 y	2 y	3 y	4 y	5-6 y	7-11 y	12-17 y	≥18 y	All age groups
Male	N	16	36	70	32	32	17	24	31	20	7	285
	Seropositive cases (%)	11 (69)	7 (19)	13 (19)	14 (44)	15 (47)	13 (76)	22 (92)	30 (97)	19 (95)	7 (100)	151 (53)
	GMT	9.2	7.6	9.1	16.8	17.6	27.7	43.6	54.1	26.4	22.1	23.4
Female	N	14	19	40	33	26	14	19	41	41	47	294
	Seropositive cases (%)	9 (64)	2 (11)	10 (25)	11 (33)	13 (50)	9 (64)	16 (84)	37 (90)	39 (95)	45 (96)	191 (65)
	GMT	12.8	7.1	10.1	15.1	15.1	19.5	37.9	42.8	51.5	30.4	24.2

Figure S2 Seropositivity of NT antibodies against EV71 (A) and CA16 (B) by gender.